UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000025050 |
|---|---|
| Receipt number | R000028831 |
| Scientific Title | Efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C |
| Date of disclosure of the study information | 2016/11/29 |
| Last modified on | 2024/12/05 12:24:18 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C
Acronym
EBR/GZR
Scientific Title
Efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C
Scientific Title:Acronym
EBR/GZR
Region
| Japan |
Condition
Condition
Patients with chronic hepatitis C virus infection
Classification by specialty
| Medicine in general | Hepato-biliary-pancreatic medicine |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
To assessment of efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatits C.
To investigate the relative factor with antiviral effect, emergence of drug-resistant virus and the suppressive effect for incidence of hepatocellular carcinoma.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Sustained virologic response rate
Safety
Cumulative incidence of hepatocellular carcinoma
Key secondary outcomes
The factor associated with sustained virologic response
Emergence of drug-resistant virus
The factor associated with incidence of hepatocellular carcinoma
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Patients with 20 years of age and older
2) Chronic hepatitis or compensated cirrhosis patients with HCV serogroup 1
3) Eligible patients for elbasvir and grazoprevir
Key exclusion criteria
1) Contraindication to elbasvir or grazoprevir
2) Contraindication to elbasvir and grazoprevir
Target sample size
500
Research contact person
Name of lead principal investigator
| 1st name | Tetsuo |
| Middle name | |
| Last name | Takehara |
Organization
Osaka University Graduate School of Medicine
Division name
Department of Gastroenterology and Hepatology
Zip code
5650871
Address
2-2 Yamadaoka, Suita, Osaka, Japan
TEL
+81-6-6879-3621
takehara@gh.med.osaka-u.ac.jp
Public contact
Name of contact person
| 1st name | Yuki |
| Middle name | |
| Last name | Tahata |
Organization
Osaka University Graduate School of Medicine
Division name
Department of Gastroenterology and Hepatology
Zip code
5650871
Address
2-2 Yamadaoka, Suita, Osaka, Japan
TEL
+81-6-6879-3621
Homepage URL
yuki.tahata@gh.med.osaka-u.ac.jp
Sponsor or person
Institute
Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology
Institute
Department
Personal name
Funding Source
Organization
Grant-in-aid from Japan Agency fir Medical Research and Development
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Osaka University Clinical Research Review Committee
Address
Yamadaoka 2-2, Suita city, Osaka
Tel
06-6210-8296
rinri@hp-crc.med.osaka-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2016 | Year | 11 | Month | 29 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
216
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2016 | Year | 11 | Month | 16 | Day |
Date of IRB
| 2016 | Year | 11 | Month | 16 | Day |
Anticipated trial start date
| 2016 | Year | 11 | Month | 18 | Day |
Last follow-up date
| 2026 | Year | 12 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
To assessment of efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatits C.
To investigate the relative factor with antiviral effect, emergence of drug-resistant virus and the suppressive effect for incidence of hepatocellular carcinoma.
Management information
Registered date
| 2016 | Year | 11 | Month | 29 | Day |
Last modified on
| 2024 | Year | 12 | Month | 05 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028831
